BioDuro and SGX Partner Up to Improve Efficiencies in Complex Drug Development
The companies will combine a drug discovery platform and a novel framework to reduce the cost and time it takes to develop complex therapies.
Contract research, development, and manufacturing organization (CRDMO), BioDuro, has partnered with chemical biology company, Silicogenix (SGX), with the aim of speeding up drug discovery for complex diseases. The partnership, which was announced in a June 10, 2025 press release (1), will see BioDuro combine its drug discovery platform with SGX’s novel framework to reduce the cost and time it takes to develop complex therapies.
“We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery,” said Dr. Subas Sakya, Chief Scientific Officer at BioDuro, in the press release (1). “We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives.”
While estimates of costs for developing a new drug range significantly, there is consensus that R&D costs are increasing over time, particularly for more complex therapeutic candidates (2). In light of this challenge, SGX has drawn upon pharmaceutical and artificial intelligence (AI) experience to develop proprietary, ultra-fast, and high-throughput frameworks that allow companies to rapidly initiate and test new therapies — including possible combinations with standard-of-care treatments. Therefore, through combining these frameworks with BioDuro’s fully integrated drug discovery platform, the companies are hoping to accelerate the development timeframe.
“This is a pivotal moment for the biopharmaceutical industry, and this partnership is a significant step forward for how novel treatments for complex and rare diseases can be quickly brought to market,” added Dr. Shailesh Date, Co-founder of Silicogenix, in the press release (1). “BioDuro is an undisputed leader and we believe our collective approach will help biopharmaceutical companies greatly expedite the development cycle for therapeutics that address unmet medical needs.”
Unmet medical need has been an important topic for pharmaceutical scientists since the beginning; however, meeting these needs is becoming a priority for many companies and is driving innovation and direction within the field of pharmaceutical sciences (3).
References
BioDuro. BioDuro Partners with Silicogenix to Accelerate Novel Drug Discovery for Complex Diseases. Press Release, June 10, 2025.
Schlander, M.; Hernandez-Villafuerte, K.; Cheng, C.-Y.; Mestre-Ferrandiz, J.; Baumann, M. How Much Does it Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics, 2021, 39, 1243–1269.
Kusynová, Z.; Pauletti, G.M.; van dem Ham, H.A.; Leufkens, H.G.M.; Mantel-Teeuwisse, A.K. Unmet Medical Need as a Driver for Pharmaceutical Sciences — A Survey Among Scientists. J. Pharm Sci., 2022, 111 (5), 1318–1324.